Inhibitor Therapeutics, Inc. – OTC:INTI
Inhibitor Therapeutics stock price today
Inhibitor Therapeutics stock price monthly change
Inhibitor Therapeutics stock price quarterly change
Inhibitor Therapeutics stock price yearly change
Inhibitor Therapeutics key metrics
Market Cap | 22.98M |
Enterprise value | 19.20M |
P/E | 1.25 |
EV/Sales | N/A |
EV/EBITDA | -72.99 |
Price/Sales | N/A |
Price/Book | -4.68 |
PEG ratio | 0.01 |
EPS | -0.01 |
Revenue | N/A |
EBITDA | -3.36M |
Income | -3.17M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInhibitor Therapeutics stock price history
Inhibitor Therapeutics stock forecast
Inhibitor Therapeutics financial statements
| Jun 2023 | 0 | -654.52K | |
|---|---|---|---|
| Sep 2023 | 0 | -664.76K | |
| Dec 2023 | 0 | -1.16M | |
| Mar 2024 | 0 | -684.71K |
| Payout ratio | 0% |
|---|
| 2019 | 0.48% |
|---|---|
| 2020 | 0.77% |
| 2021 | |
| 2022 | |
| 2023 |
| Jun 2023 | 10158334 | 3.04M | 29.96% |
|---|---|---|---|
| Sep 2023 | 9607689 | 3.15M | 32.85% |
| Dec 2023 | 8949155 | 3.66M | 40.96% |
| Mar 2024 | 7794220 | 3.15M | 40.49% |
| Jun 2023 | -682.61K | 0 | 0 |
|---|---|---|---|
| Sep 2023 | -562.70K | 0 | 0 |
| Dec 2023 | -697.70K | 0 | 0 |
| Mar 2024 | -1.15M | 0 | 0 |
Inhibitor Therapeutics alternative data
| Aug 2023 | 3 |
|---|---|
| Sep 2023 | 3 |
| Oct 2023 | 3 |
| Nov 2023 | 3 |
| Dec 2023 | 3 |
| Jan 2024 | 3 |
| Feb 2024 | 3 |
| Mar 2024 | 3 |
| Apr 2024 | 3 |
| May 2024 | 3 |
| Jun 2024 | 3 |
| Jul 2024 | 3 |
Inhibitor Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Dec 2019 | 14000 | 0 |
| Insider | Compensation |
|---|---|
Mr. Nicholas Jon Virca (1946) Pres & Chief Executive Officer | $144,680 |
Mr. Garrison J. Hasara CPA, CPA (1969) Chief Financial Officer, Treasurer, Corporation Sec. & Chief Compliance Officer | $137,750 |
Thursday, 5 December 2024 | ||
| Complement Inhibitor Therapeutics Pipeline Developments Research Report 2024 | globenewswire.com | |
Monday, 28 October 2024 | ||
| Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor Therapeutics | DelveInsight | globenewswire.com | |
Thursday, 22 August 2024 | ||
| Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan | globenewswire.com | |
Wednesday, 22 May 2024 | ||
| 3 Intriguing Stocks to Watch as Earnings Approach | zacks.com |
-
What's the price of Inhibitor Therapeutics stock today?
One share of Inhibitor Therapeutics stock can currently be purchased for approximately $0.06.
-
When is Inhibitor Therapeutics's next earnings date?
Unfortunately, Inhibitor Therapeutics's (INTI) next earnings date is currently unknown.
-
Does Inhibitor Therapeutics pay dividends?
No, Inhibitor Therapeutics does not pay dividends.
-
How much money does Inhibitor Therapeutics make?
Inhibitor Therapeutics has a market capitalization of 22.98M.
-
What is Inhibitor Therapeutics's stock symbol?
Inhibitor Therapeutics, Inc. is traded on the OTC under the ticker symbol "INTI".
-
What is Inhibitor Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Inhibitor Therapeutics?
Shares of Inhibitor Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Inhibitor Therapeutics's key executives?
Inhibitor Therapeutics's management team includes the following people:
- Mr. Nicholas Jon Virca Pres & Chief Executive Officer(age: 79, pay: $144,680)
- Mr. Garrison J. Hasara CPA, CPA Chief Financial Officer, Treasurer, Corporation Sec. & Chief Compliance Officer(age: 56, pay: $137,750)
-
How many employees does Inhibitor Therapeutics have?
As Jul 2024, Inhibitor Therapeutics employs 3 workers.
-
When Inhibitor Therapeutics went public?
Inhibitor Therapeutics, Inc. is publicly traded company for more then 27 years since IPO on 30 Oct 1997.
-
What is Inhibitor Therapeutics's official website?
The official website for Inhibitor Therapeutics is inhibitortx.com.
-
Where are Inhibitor Therapeutics's headquarters?
Inhibitor Therapeutics is headquartered at 4830 West Kennedy Boulevard, Tampa, FL.
-
How can i contact Inhibitor Therapeutics?
Inhibitor Therapeutics's mailing address is 4830 West Kennedy Boulevard, Tampa, FL and company can be reached via phone at +81 38642559.
Inhibitor Therapeutics company profile:
Inhibitor Therapeutics, Inc.
inhibitortx.comOTC
1
Biotechnology
Healthcare
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
Tampa, FL 33602
CIK: 0001042418
ISIN: US45720M1053
CUSIP: 45720M105
